Management of Leprosy Type 1 (reversal) Reactions
Keywords:
Leprosy, reversal type 1, ManagementAbstract
The author conducted documentary research on randomized controlled trials (RTC) of the management of Type 1 Reactions by complete review of relating evidences from Cochrane Clinical trails PubMed and Clinical researches in Thailand up to February 2009. Overall results revealed that there were four RTCs which indicated management of Type 1 Reactions by oral corticosteroids. However, there were lacking of adequate evidences on acceptable dosages and duration of such treatment. Only one research showed definite results of treatment by prednisolone regimen (total dose 2.31 grammes) for 5 months were less likely to need additional prednisolone than those treated with a 3 month course of prednisolone (total dose 2.94 g). This study did not use nerve function as an outcome measure. The improvement in nerve function impairment with steroid treatment in highly variable, with 33-73% of nerve recovering fully. As size of sample was too small for making significant conclusion which regimens of corticosteroid were appropriate and most effective for management of Type 1 Reactions. Further clinical trials, therefore were recommended to make more advances in treatment of Type 1 Reactions.
References
1. Ranque B, Nguyen VT, Vu HT et al. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis, 2007; 44: 33-40.
2. Saunderson P, Geber S, Desta K et al. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev, 2000; 71: 285- 308.
3. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
4. Ridley DS, Jopling WH. Classification of leprosy according to immunity. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
5. Modlin RL, Melancon-Kaplan J, Young SM et al. Learning from Lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA, 1988; 85:n1213-1217.
6. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis, 2004; 72: 125-133.
7. Lockwood DN, Lucas SB, Desikan K, et al. The histological diagnosis of leprosy Type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol, 2008 March 6.
8. van Brakel WH, Nicholls PG, Das L et al. The INFIR cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev, 2005; 76: 14-34.
9. van Brakel WH, Nicholls PG, Wilder-Smith EP et al Early Diagnosis of Neuropathy in Leprosy- Comparing Diagnostic Tests in a Large Prospective Study (the INFIR Cohort Study). PLoS Negl Trop Dis, 2008; 2: e212.
10. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand. 1987-1995 [correction of 1978-1995]. II. Reactions Int J Lepr Other Mycobact Dis 1998, 1998; 66: 159-169.
11. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev, 1994; 65: 190-203.
12. Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis, 1999; 67: 6-12.
13. Saunderson P, Gebre S, Byass P. Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev, 2000; 71: 309-317.
14. Sarno EN, Illarramendi X, Nery JA et al. HIVM. leprae interaction: can HAART modify the course of leprosy? Public Health Rep, 2008; 123: 206-212.
15. Deps PD, Lockwood DN. Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg, 2008; 102: 966-968.
16. Job CK. Pathology of leprosy. In: Hastings RC (ed). Leprosy, 2nd edn. Churchill Livingstone, Edinburgh, 1994; pp. 193-234.
17. Lockwood DN, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg, 2002; 66: 409-415.
18. Sousa AL, Stefani MM, Pereira GA et al. Mycobacterium leprae DNA Associated with Type 1 Reactions in Single Lesion Paucibacillary Leprosy Treated with Single Dose Rifampin, Ofloxacin, and Minocycline. Am J Trop Med Hyg, 2007; 77: 829-833.
19. Oliveira RB, Ochoa MT, Sieling PA et al. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun, 2003; 71: 1427-1433.
20. Ochoa MT, Stenger S, Sieling PA et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med, 2001; 7: 174-179.
21. Bochud PY, Hawn TR, Siddiqui MR et al. Tolllike receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis, 2008; 197: 253-261.
22. Misch EA, Macdonald M, Ranjit C et al. Human TLR1 Deficiency Is Associated with Impaired Mycobacterial Signaling and Protection from Leprosy Reversal Reaction. PLoS Negl Trop Dis, 2008; 2: e231.
23. Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol, 2007; 178: 7520-7524.
24. Khanolkar-Young S, Rayment N, Brickell PM et al. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol, 1995; 99: 196-
202.
25. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun, 22001; 69: 3413-3417.
26. Kirkaldy AA, Musonda AC, Khanolkhar-Young S et al. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol, 2003; 134: 447-453.
27. Andersson AK, Chaduvula M, Atkinson SE et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun, 2005; 73: 3725-3733.
28. Simmons CP, Thwaites GE, Quyen NT et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol, 2005; 175: 579-590.
29. Andersson AK, Atkinson SE, Khanolkar-Young S et al. Alteration of the cortisol- cortisone shuttle in leprosy type 1 reactions in leprosy patients is Hyderabad, India. Immunol Lett. 2007; 109: 72-75.
30. Lockwood DN, Vinayakumar S, Stanley JN et al. Clinical features and outcome of reversal (type 1 ) reactions in Hyderabad, India. In K Lepr Other Mycobact Dis, 1993; 61: 8-15.
31. Santaram V, Porichha D. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis. Indian J Lepr, 2004; 76: 310-320.
32. Hogeweg M, Kiran KU, Suneetha S. The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients. Lepr Rev, 1991;
62: 143-149.
33. Ponnighaus JM, Boerrigter G. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Int J Lepr Other Mycobact Dis, 1995; 63: 1-7.
34. Scollard DM, Smith T, Bhoopat L et al. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis, 1994; 62: 559-567.
35. Richardus JH, Finlay KM, Croft RP, Smith WC. Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh. Lepr Rev, 1996; 67: 297-305.
36. Richardus JH, Nicholls PG, Croft RP et al. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol, 2004; 33: 337-343.
37. Croft RP, Nicholls PG, Richardus JH, Smith WC. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 2000; 71: 18-33.
38. Van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev, 2007; CD005491.
39. Van Brakel WH, Nicholls PG, Lockwood DN et al. A scale to assess the severity of leprosy reactions. Lepr Rev, 2007; 78: 161-164.
40. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments. Int J Lepr Other Mycobact Dis, 1998; 66: 170-181.
41. Bolen S, Tilburt J, Baffi C et al. Defining 'success' in recruitment of underrepresented population to cancer clinical trials: moving toward a more consistent approach. Cancer, 2006; 106: 1197-1204.
42. Le Grand A. Women and leprosy: a review. Lepr Rev, 1997; 68: 203-211.
43. Roche M, Convit J, Medina JA, Blomenfeld E. The effects of adrenocorticotropic hormone (ACTH) in lepromatous lepra reaction. Int J Lepr, 1951; 19: 137-145.
44. Perretti M, D' Acquisto F. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm Allergy Drug Targets, 2006; 5: 107-114.
45. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol, 2006; 148: 245-254.
46. Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev, 2006; 77: 25-33.
47. Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomized placebo controlled trial (TRIPOD 1). BMJ, 2004; 328(7454): 1459.y
48. http://www.who.int/lep/resources/SEAGLP20062.pdf was accessed on 30.11.2008
49. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study-Part 2: results of steroid treatment. Lepr Rev, 1996; 67: 104-118.
50. Richardus JH, Withington SG, Anderson AM et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003; 74: 311-318.
51. Pannikar VK, Ramprasad S, Reddy NR et al. Effect of epicondylectomy in early ulnar neuritis treated with steroids. Int J Lepr Other Mycobact Dis, 1984; 52: 501-505.
52. Boucher P, Millan J, Parent M, Moulia-Pela JP. Randomized controlled trial of medical and medico-surgical treatment of Hansen's neuritis. Acta Leprol, 1999; 11: 171-177.
53. Marlowe SN, Hawksworth RA, Butlin CR et al. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg, 20004; 98: 602-609.
54. Marlowe SN, Leekassa R, Bizuneh E et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg, 2007; 101: 1004-1012.
55. Bwire R, Kawuma HJ. Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Trans R Soc Trip Med Hyg, 1994; 88: 315-316.
56. Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis, 2003; 36: e5-e6.
57. Van Brakel WH, Saunderson P, Shetty V et al. International workshop on neuropathology in leprosy- consensus report. Lepr Rev, 2007; 78: 416-433.
58. Leang B, Lynen L, Tootill R et al. Death caused by strongyloides hyperinfection in a leprosy patient on treatment for a type II leprosy reaction. Lepr Rev, 2003; 75: 398-403.
59. Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002; 61: 718-722.
60. http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/Glucocorticoid.pdf was accessed on 30.11.2008
61. Inhikawa S, Ishikawa A, Yoh K et al. Osteoporo sis in male and female leprosy patients. Calcif Tissue Int, 1999; 64: 144-147.
62. Gurwitz JH, Bohn RL, Glynn RJ et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med, 1994; 154: 97-101.
63. Sugumaran DS. Leprosy reactions-complications of steroid therapy. Int J Lepr Other Mycobact Dis, 1998; 66: 10-15.
64. Hogeweg M, Keunen JE. Prevention of blindness in leprosy and the role of the Vision Programme. Eye, 2020; 19: 1099-1105.
65. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev, 2003; 74: 319-327.
66. Nery JA, Vieira LM, de Matos HJ et al. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo, 1998; 40: 363-370.
67. Van Brakel WH, Anderson AM, Withington SG, et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 300-310.
68. Wilder-Smith A, Wilder-Smith E. Effect of steroid therapy on parameters of peripheral autonomic dysfunction in leprosy patients with acute neuritis. Int J Lepr Other Mycobact Dis, 1997; 65: 20-27.
69. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Lepr Rev, 1985; 56: 127-134.
70. Touw-Langendijk EM, Brandsma JW, Andersen JG. Treatment of ulnar and median nerve function loss in borderline leprosy. Lepr Rev, 1984; 55: 41-46.
71. Bernink EH, Voskens JE. Study on the detection of leprosy reactions and the effect of prednisone on various nerves, Indonesia. Lepr Rev, 1997; 68: 225-232.
72. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and rehabilitation Training
Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis, 1992; 60: 173-184.
73. Kiran Ku, Hogeweg M, Suneetha S. Treatment of recent facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Lepr Rev, 1991; 62: 150-154.
74. Naafs B, Pearson JM, Wheate HW. Reversal reaction: the prevention of permanent nerve damage. Comparison of short and long-term steroid treatment. Int J Lepr Other Mycobact Dis, 1979; 47: 7-12
75. สถาบันราชประชาสมาสัย กรมควบคุมโรค.คู่มือการวินิจฉัย และรักษาโรคเรื้อน.กรุงเทพมหานคร. 2550;1-20.
76. Hastings,R.C.(editor) (1994) Leprosy.(second edition).London: Churchill Livingstone.
77. BK Girdhar, A GirdHar and JK Chakma, Advances in the treatment of reactions in Leprosy, Indain J lepr 2007; 79: (2 and 3): 121-134.
78. Salmaggi A, Corjini E, La Mantia L et al. Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Nevrol 1997; 244: 167-174.
2. Saunderson P, Geber S, Desta K et al. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev, 2000; 71: 285- 308.
3. Croft RP, Nicholls PG, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
4. Ridley DS, Jopling WH. Classification of leprosy according to immunity. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
5. Modlin RL, Melancon-Kaplan J, Young SM et al. Learning from Lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA, 1988; 85:n1213-1217.
6. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis, 2004; 72: 125-133.
7. Lockwood DN, Lucas SB, Desikan K, et al. The histological diagnosis of leprosy Type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol, 2008 March 6.
8. van Brakel WH, Nicholls PG, Das L et al. The INFIR cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev, 2005; 76: 14-34.
9. van Brakel WH, Nicholls PG, Wilder-Smith EP et al Early Diagnosis of Neuropathy in Leprosy- Comparing Diagnostic Tests in a Large Prospective Study (the INFIR Cohort Study). PLoS Negl Trop Dis, 2008; 2: e212.
10. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand. 1987-1995 [correction of 1978-1995]. II. Reactions Int J Lepr Other Mycobact Dis 1998, 1998; 66: 159-169.
11. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev, 1994; 65: 190-203.
12. Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis, 1999; 67: 6-12.
13. Saunderson P, Gebre S, Byass P. Reversal reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev, 2000; 71: 309-317.
14. Sarno EN, Illarramendi X, Nery JA et al. HIVM. leprae interaction: can HAART modify the course of leprosy? Public Health Rep, 2008; 123: 206-212.
15. Deps PD, Lockwood DN. Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg, 2008; 102: 966-968.
16. Job CK. Pathology of leprosy. In: Hastings RC (ed). Leprosy, 2nd edn. Churchill Livingstone, Edinburgh, 1994; pp. 193-234.
17. Lockwood DN, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg, 2002; 66: 409-415.
18. Sousa AL, Stefani MM, Pereira GA et al. Mycobacterium leprae DNA Associated with Type 1 Reactions in Single Lesion Paucibacillary Leprosy Treated with Single Dose Rifampin, Ofloxacin, and Minocycline. Am J Trop Med Hyg, 2007; 77: 829-833.
19. Oliveira RB, Ochoa MT, Sieling PA et al. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun, 2003; 71: 1427-1433.
20. Ochoa MT, Stenger S, Sieling PA et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med, 2001; 7: 174-179.
21. Bochud PY, Hawn TR, Siddiqui MR et al. Tolllike receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis, 2008; 197: 253-261.
22. Misch EA, Macdonald M, Ranjit C et al. Human TLR1 Deficiency Is Associated with Impaired Mycobacterial Signaling and Protection from Leprosy Reversal Reaction. PLoS Negl Trop Dis, 2008; 2: e231.
23. Johnson CM, Lyle EA, Omueti KO et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol, 2007; 178: 7520-7524.
24. Khanolkar-Young S, Rayment N, Brickell PM et al. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol, 1995; 99: 196-
202.
25. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun, 22001; 69: 3413-3417.
26. Kirkaldy AA, Musonda AC, Khanolkhar-Young S et al. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol, 2003; 134: 447-453.
27. Andersson AK, Chaduvula M, Atkinson SE et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun, 2005; 73: 3725-3733.
28. Simmons CP, Thwaites GE, Quyen NT et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol, 2005; 175: 579-590.
29. Andersson AK, Atkinson SE, Khanolkar-Young S et al. Alteration of the cortisol- cortisone shuttle in leprosy type 1 reactions in leprosy patients is Hyderabad, India. Immunol Lett. 2007; 109: 72-75.
30. Lockwood DN, Vinayakumar S, Stanley JN et al. Clinical features and outcome of reversal (type 1 ) reactions in Hyderabad, India. In K Lepr Other Mycobact Dis, 1993; 61: 8-15.
31. Santaram V, Porichha D. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis. Indian J Lepr, 2004; 76: 310-320.
32. Hogeweg M, Kiran KU, Suneetha S. The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients. Lepr Rev, 1991;
62: 143-149.
33. Ponnighaus JM, Boerrigter G. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Int J Lepr Other Mycobact Dis, 1995; 63: 1-7.
34. Scollard DM, Smith T, Bhoopat L et al. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis, 1994; 62: 559-567.
35. Richardus JH, Finlay KM, Croft RP, Smith WC. Nerve function impairment in leprosy at diagnosis and at completion of MDT: a retrospective cohort study of 786 patients in Bangladesh. Lepr Rev, 1996; 67: 297-305.
36. Richardus JH, Nicholls PG, Croft RP et al. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol, 2004; 33: 337-343.
37. Croft RP, Nicholls PG, Richardus JH, Smith WC. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 2000; 71: 18-33.
38. Van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev, 2007; CD005491.
39. Van Brakel WH, Nicholls PG, Lockwood DN et al. A scale to assess the severity of leprosy reactions. Lepr Rev, 2007; 78: 161-164.
40. Schreuder PA. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. III. Neural and other impairments. Int J Lepr Other Mycobact Dis, 1998; 66: 170-181.
41. Bolen S, Tilburt J, Baffi C et al. Defining 'success' in recruitment of underrepresented population to cancer clinical trials: moving toward a more consistent approach. Cancer, 2006; 106: 1197-1204.
42. Le Grand A. Women and leprosy: a review. Lepr Rev, 1997; 68: 203-211.
43. Roche M, Convit J, Medina JA, Blomenfeld E. The effects of adrenocorticotropic hormone (ACTH) in lepromatous lepra reaction. Int J Lepr, 1951; 19: 137-145.
44. Perretti M, D' Acquisto F. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm Allergy Drug Targets, 2006; 5: 107-114.
45. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol, 2006; 148: 245-254.
46. Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev, 2006; 77: 25-33.
47. Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomized placebo controlled trial (TRIPOD 1). BMJ, 2004; 328(7454): 1459.y
48. http://www.who.int/lep/resources/SEAGLP20062.pdf was accessed on 30.11.2008
49. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study-Part 2: results of steroid treatment. Lepr Rev, 1996; 67: 104-118.
50. Richardus JH, Withington SG, Anderson AM et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003; 74: 311-318.
51. Pannikar VK, Ramprasad S, Reddy NR et al. Effect of epicondylectomy in early ulnar neuritis treated with steroids. Int J Lepr Other Mycobact Dis, 1984; 52: 501-505.
52. Boucher P, Millan J, Parent M, Moulia-Pela JP. Randomized controlled trial of medical and medico-surgical treatment of Hansen's neuritis. Acta Leprol, 1999; 11: 171-177.
53. Marlowe SN, Hawksworth RA, Butlin CR et al. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg, 20004; 98: 602-609.
54. Marlowe SN, Leekassa R, Bizuneh E et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg, 2007; 101: 1004-1012.
55. Bwire R, Kawuma HJ. Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Trans R Soc Trip Med Hyg, 1994; 88: 315-316.
56. Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis, 2003; 36: e5-e6.
57. Van Brakel WH, Saunderson P, Shetty V et al. International workshop on neuropathology in leprosy- consensus report. Lepr Rev, 2007; 78: 416-433.
58. Leang B, Lynen L, Tootill R et al. Death caused by strongyloides hyperinfection in a leprosy patient on treatment for a type II leprosy reaction. Lepr Rev, 2003; 75: 398-403.
59. Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002; 61: 718-722.
60. http://www.rcplondon.ac.uk/pubs/books/glucocorticoid/Glucocorticoid.pdf was accessed on 30.11.2008
61. Inhikawa S, Ishikawa A, Yoh K et al. Osteoporo sis in male and female leprosy patients. Calcif Tissue Int, 1999; 64: 144-147.
62. Gurwitz JH, Bohn RL, Glynn RJ et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med, 1994; 154: 97-101.
63. Sugumaran DS. Leprosy reactions-complications of steroid therapy. Int J Lepr Other Mycobact Dis, 1998; 66: 10-15.
64. Hogeweg M, Keunen JE. Prevention of blindness in leprosy and the role of the Vision Programme. Eye, 2020; 19: 1099-1105.
65. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev, 2003; 74: 319-327.
66. Nery JA, Vieira LM, de Matos HJ et al. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo, 1998; 40: 363-370.
67. Van Brakel WH, Anderson AM, Withington SG, et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 300-310.
68. Wilder-Smith A, Wilder-Smith E. Effect of steroid therapy on parameters of peripheral autonomic dysfunction in leprosy patients with acute neuritis. Int J Lepr Other Mycobact Dis, 1997; 65: 20-27.
69. Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Lepr Rev, 1985; 56: 127-134.
70. Touw-Langendijk EM, Brandsma JW, Andersen JG. Treatment of ulnar and median nerve function loss in borderline leprosy. Lepr Rev, 1984; 55: 41-46.
71. Bernink EH, Voskens JE. Study on the detection of leprosy reactions and the effect of prednisone on various nerves, Indonesia. Lepr Rev, 1997; 68: 225-232.
72. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and rehabilitation Training
Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis, 1992; 60: 173-184.
73. Kiran Ku, Hogeweg M, Suneetha S. Treatment of recent facial nerve damage with lagophthalmos, using a semistandardized steroid regimen. Lepr Rev, 1991; 62: 150-154.
74. Naafs B, Pearson JM, Wheate HW. Reversal reaction: the prevention of permanent nerve damage. Comparison of short and long-term steroid treatment. Int J Lepr Other Mycobact Dis, 1979; 47: 7-12
75. สถาบันราชประชาสมาสัย กรมควบคุมโรค.คู่มือการวินิจฉัย และรักษาโรคเรื้อน.กรุงเทพมหานคร. 2550;1-20.
76. Hastings,R.C.(editor) (1994) Leprosy.(second edition).London: Churchill Livingstone.
77. BK Girdhar, A GirdHar and JK Chakma, Advances in the treatment of reactions in Leprosy, Indain J lepr 2007; 79: (2 and 3): 121-134.
78. Salmaggi A, Corjini E, La Mantia L et al. Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Nevrol 1997; 244: 167-174.
Downloads
Published
2011-03-31
How to Cite
1.
อรรถเศรษฐ ว. Management of Leprosy Type 1 (reversal) Reactions. Dis Control J [Internet]. 2011 Mar. 31 [cited 2024 May 22];37(1):60-74. Available from: https://he01.tci-thaijo.org/index.php/DCJ/article/view/155647
Issue
Section
Review Article
License
Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.
.png){kind=logo}
